Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Dainippon’s Sunovion Acquires Elevation
by Rick Mullin
September 10, 2012
| A version of this story appeared in
Volume 90, Issue 37
Sunovion Pharmaceuticals has acquired Elevation Pharmaceuticals, a specialist in aerosol therapies for respiratory diseases. The acquisition includes Elevation’s EP-101, a long-acting bronchodilator in Phase II clinical trials for the treatment of chronic obstructive pulmonary disease. Sunovion, a subsidiary of Dainippon Sumitomo Pharma, will pay $100 million to Elevation’s shareholders plus developmental milestone payments of up to $90 million and commercial milestone payments of up to $210 million. Sunovion was called Sepracor until Dainippon Sumitomo acquired it in 2009.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter